

NOTIFICATION OF ATTENDANCE AND FORM FOR ADVANCE VOTING

by postal voting in accordance with Section 22 of the Act (2020:198) on temporary exceptions to facilitate the execution of general meetings in companies and other associations

The form must be received by Oncopeptides AB (publ) no later than Tuesday, 25 May 2021.

The shareholder set out below hereby notifies the company of its participation and exercises its voting right for all of the shareholder's shares in Oncopeptides AB (publ), Reg. No. 556596-6438 at the Annual General Meeting on Wednesday, 26 May 2021. The voting right is exercised in accordance with the voting options marked below.

Shareholder	Personal identity number/registration number

Assurance (if the undersigned is a legal representative of a shareholder who is a legal entity): I, the undersigned, am a board member, the CEO or a signatory of the shareholder and solemnly declare that I am authorised to submit this advance vote on behalf of the shareholder and that the contents of the advance vote correspond to the shareholder's decisions

Assurance (if the undersigned represents the shareholder by proxy): I, the undersigned, solemnly declare that the enclosed power of attorney corresponds to the original and that it has not been revoked

Place and date
Signature
Clarification of signature

Telephone number	E-mail

Instructions to vote in advance:

- Complete the shareholder information above
- Select the preferred voting options below
- Print, sign and send the form in the original to Oncopeptides AB (publ), Luntmakargatan 46, SE-111 37 Stockholm, Sweden. A completed and signed form may also be submitted electronically and shall, in that case, be sent to lisa.andersson@oncopeptides.com
- If the shareholder is a natural person who is personally voting in advance, it is the shareholder who should sign under *Signature* above. If the advance vote is submitted by a proxy of the shareholder, it is the proxy who should sign. If the advance vote is submitted by a legal representative of a legal entity, it is the representative who should sign
- A power of attorney shall be enclosed with the form if the shareholder votes in advance by proxy. If the shareholder is a legal entity, a registration certificate or a corresponding document for the legal entity shall be enclosed with the form
- **Please note that a shareholder whose shares are registered in the name of a bank or securities institute must re-register its shares in its own name to vote.** Instructions regarding this are included in the notice convening the meeting

A shareholder cannot give any other instructions than selecting one of the options specified at each item in the form. If a shareholder wishes to abstain from voting in relation to a matter, kindly refrain from selecting an option. A vote (*i.e.* the advance voting in its entirety) is invalid if the shareholder has provided the form with specific instructions or conditions or if pre-printed text is amended or supplemented. One form per shareholder will be considered. If more than one form is submitted, the form with the latest date will be considered. The form latest received by the company will be considered if two forms are dated at the same date. An incomplete or wrongfully completed form may be discarded without being considered.

The form, together with any enclosed authorisation documentation, shall be received by Oncopeptides no later than **Tuesday, 25 May 2021**. An advance vote can be withdrawn up to and including **Tuesday, 25 May 2021**, by contacting Oncopeptides by e-mail to lisa.andersson@oncopeptides.com or by post to Oncopeptides AB (publ), Luntmakargatan 46, SE-111 37 Stockholm, Sweden.

For complete proposals regarding the items on the agenda, kindly refer to the notice convening the meeting and the proposals on Oncopeptides' webpage.

For information on how your personal data is processed, see the integrity policy that is available at Euroclear's webpage www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.

Annual General Meeting in Oncopeptides AB (publ) on Wednesday, 26 May 2021

The voting options below comprise the proposals included in the notice convening the Annual General Meeting and have been provided on the company's website.

1. Election of chairman of the Annual General Meeting Yes <input type="checkbox"/> No <input type="checkbox"/>
2. Election of one or two persons to approve the minutes 2.1 Ulrik Grönvall or, in his absence, the one appointed by the nomination committee Yes <input type="checkbox"/> No <input type="checkbox"/>
2.2 Caroline Murray or, in her absence, the one appointed by the nomination committee Yes <input type="checkbox"/> No <input type="checkbox"/>
3. Preparation and approval of voting list Yes <input type="checkbox"/> No <input type="checkbox"/>
4. Approval of the agenda Yes <input type="checkbox"/> No <input type="checkbox"/>
5. Determination as to whether the Annual General Meeting has been duly convened Yes <input type="checkbox"/> No <input type="checkbox"/>
7. Resolutions in respect of
7a. Adoption of the profit and loss statement and balance sheet and the group profit and loss statement and group balance sheet Yes <input type="checkbox"/> No <input type="checkbox"/>
7b. Allocation of the Company's profit or loss in accordance with the adopted balance sheet Yes <input type="checkbox"/> No <input type="checkbox"/>
7c. The discharge from liability for the members of the Board of Directors and the CEO
7c. 1. Per Wold-Olsen Yes <input type="checkbox"/> No <input type="checkbox"/>
7c. 2. Brian Stuglik Yes <input type="checkbox"/> No <input type="checkbox"/>
7c. 3. Jonas Brambeck

Yes <input type="checkbox"/> No <input type="checkbox"/>
7c. 4. Cecilia Daun Wennborg Yes <input type="checkbox"/> No <input type="checkbox"/>
7c. 5. Jarl Ulf Jungnelius Yes <input type="checkbox"/> No <input type="checkbox"/>
7c. 6. Per Samuelsson Yes <input type="checkbox"/> No <input type="checkbox"/>
7c. 7. Jennifer Jackson Yes <input type="checkbox"/> No <input type="checkbox"/>
7c. 8. Jakob Lindberg Yes <input type="checkbox"/> No <input type="checkbox"/>
7c. 9. Marty J Duvall Yes <input type="checkbox"/> No <input type="checkbox"/>
8. Determination of the number of members of the Board of Directors and the number of auditors to be elected at the Annual General Meeting Yes <input type="checkbox"/> No <input type="checkbox"/>
9. Determination of directors' and auditors' fees Yes <input type="checkbox"/> No <input type="checkbox"/>
10. Election of members of the Board of Directors and Chairman of the Board of Directors
10a. Per Wold-Olsen, re-election Yes <input type="checkbox"/> No <input type="checkbox"/>
10b. Brian Stuglik, re-election Yes <input type="checkbox"/> No <input type="checkbox"/>
10c. Cecilia Daun Wennborg, re-election Yes <input type="checkbox"/> No <input type="checkbox"/>
10d. Jarl Ulf Jungnelius, re-election Yes <input type="checkbox"/> No <input type="checkbox"/>
10e. Per Samuelsson, re-election Yes <input type="checkbox"/> No <input type="checkbox"/>
10f. Jennifer Jackson, re-election Yes <input type="checkbox"/> No <input type="checkbox"/>
10g. Chairman of the Board of Directors: Per Wold-Olsen, re-election

Yes <input type="checkbox"/> No <input type="checkbox"/>
11. Election of auditor Yes <input type="checkbox"/> No <input type="checkbox"/>
12. Presentation of the Board of Directors' remuneration report for approval Yes <input type="checkbox"/> No <input type="checkbox"/>
13. Resolution on new articles of association Yes <input type="checkbox"/> No <input type="checkbox"/>
14. Resolution on the introduction of a long term incentive program for the Company's employees and contractors
14a. Proposal for resolution on adoption of a long term incentive program for the Company's employees and contractors Yes <input type="checkbox"/> No <input type="checkbox"/>
14b. Proposal regarding issue of warrants Yes <input type="checkbox"/> No <input type="checkbox"/>
14c. Proposal regarding equity swap agreement with a third party Yes <input type="checkbox"/> No <input type="checkbox"/>
15. Resolution on the introduction of a long term performance based incentive program for certain members of the Board of Directors
15a. Proposal for resolution on adoption of a long term performance based incentive program for certain members of the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
15b. Proposal regarding issue of warrants Yes <input type="checkbox"/> No <input type="checkbox"/>
15c. Equity swap agreement with a third party Yes <input type="checkbox"/> No <input type="checkbox"/>
16. Resolution regarding authorization for the Board of Directors to resolve upon issues of shares, warrants and/or convertibles
16a. Main proposal Yes <input type="checkbox"/> No <input type="checkbox"/>
16b. Alternative proposal Yes <input type="checkbox"/> No <input type="checkbox"/>
17. Resolution on guidelines for remuneration to senior management Yes <input type="checkbox"/> No <input type="checkbox"/>

**The shareholder wishes that the resolutions under one or several items in the form above be deferred to a continued General Meeting
(Completed only if the shareholder has such a wish)**

Item/items (use numbering):